HARP Harpoon Therapeutics Inc.

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Date	Price Target	Rating	Analyst
1/5/2024	$23.00	Outperform	Oppenheimer
11/20/2023		Outperform	TD Cowen
7/6/2022	$16.00	Buy	Canaccord Genuity
11/11/2021	$25.00 → $19.00	Outperform	SVB Leerink
9/28/2021	$16.00	Neutral → Buy	Citigroup
8/6/2021	$29.00 → $25.00	Outperform	SVB Leerink

Harpoon Therapeutics Inc.

Peers

Recent Analyst Ratings for Harpoon Therapeutics Inc.

Harpoon Therapeutics Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Merck & Co., Inc. bought $492,135,715 worth of shares (21,397,205 units at $23.00) (SEC Form 4)

Harpoon Therapeutics Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

New Leaf Biopharma Opportunities Ii, L.P. returned 1,859,169 shares to the company and returned 10,000 units of 8.000% Series A Redeemable Preferred Stock to the company (SEC Form 4)

Hunt Ronald was granted 424 shares, returned 1,872,393 shares to the company and returned 10,000 units of 8.000% Series A Redeemable Preferred Stock to the company, closing all direct ownership in the company (SEC Form 4)

Silvernail Lauren P returned 5,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

Walker Luke Nathaniel returned 135,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

Myers Scott Dunseth returned 22,665 shares to the company, closing all direct ownership in the company (SEC Form 4)

Chin Mark returned 13,224 shares to the company and was granted 424 shares, closing all direct ownership in the company (SEC Form 4)

Drachman Jonathan G was granted 415 shares and returned 5,415 shares to the company, closing all direct ownership in the company (SEC Form 4)

Robbins Andrew R returned 5,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

Lanza Frank J returned 18,734 shares to the company, closing all direct ownership in the company (SEC Form 4)

Eastland Julia Marie returned 269,381 shares to the company and was granted 31,250 shares, closing all direct ownership in the company (SEC Form 4)